The CheckMate 722 trial (NCT02864251) is a currently active phase 3 study of patients with EGFRm, T790M-negative recurrent or stage IV NSCLC who have previously been treated with EGFR TKI therapy (66). This evidence concerns the gene EGFR and non-small cell lung carcinoma.